| 000 | 02793 a2200829 4500 | ||
|---|---|---|---|
| 005 | 20250516143531.0 | ||
| 264 | 0 | _c20131107 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a1097-0215 | ||
| 024 | 7 |
_a10.1002/ijc.28199 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDai, Congxin | |
| 245 | 0 | 0 |
_aPyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. _h[electronic resource] |
| 260 |
_bInternational journal of cancer _cOct 2013 |
||
| 300 |
_a1982-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
| 650 | 0 | 4 |
_aCaspase 7 _xmetabolism |
| 650 | 0 | 4 |
_aCaspase 9 _xmetabolism |
| 650 | 0 | 4 |
_aCathepsin B _xbiosynthesis |
| 650 | 0 | 4 |
_aCell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCytochromes c _xmetabolism |
| 650 | 0 | 4 | _aDNA Damage |
| 650 | 0 | 4 |
_aDacarbazine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFolic Acid Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aHistones _xmetabolism |
| 650 | 0 | 4 |
_aLeucovorin _xpharmacology |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 2 _xbiosynthesis |
| 650 | 0 | 4 |
_aMatrix Metalloproteinase 9 _xbiosynthesis |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred NOD |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 |
_aMitochondria _xdrug effects |
| 650 | 0 | 4 | _aNeoplasm Invasiveness |
| 650 | 0 | 4 | _aNeoplasm Transplantation |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aPituitary Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPoly (ADP-Ribose) Polymerase-1 |
| 650 | 0 | 4 |
_aPoly(ADP-ribose) Polymerases _xmetabolism |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xbiosynthesis |
| 650 | 0 | 4 |
_aPyrimethamine _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aTemozolomide |
| 650 | 0 | 4 |
_aUp-Regulation _xdrug effects |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 650 | 0 | 4 |
_abcl-2-Associated X Protein _xbiosynthesis |
| 700 | 1 | _aZhang, Bo | |
| 700 | 1 | _aLiu, Xiaohai | |
| 700 | 1 | _aGuo, Kai | |
| 700 | 1 | _aMa, Sihai | |
| 700 | 1 | _aCai, Feng | |
| 700 | 1 | _aYang, Yakun | |
| 700 | 1 | _aYao, Yong | |
| 700 | 1 | _aFeng, Ming | |
| 700 | 1 | _aBao, Xinjie | |
| 700 | 1 | _aDeng, Kan | |
| 700 | 1 | _aJiao, Yonghui | |
| 700 | 1 | _aWei, Zhenqing | |
| 700 | 1 | _aJunji, Wei | |
| 700 | 1 | _aXing, Bing | |
| 700 | 1 | _aLian, Wei | |
| 700 | 1 | _aWang, Renzhi | |
| 773 | 0 |
_tInternational journal of cancer _gvol. 133 _gno. 8 _gp. 1982-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ijc.28199 _zAvailable from publisher's website |
| 999 |
_c22648702 _d22648702 |
||